A Study for Patients With Secondary Progressive Multiple Sclerosis

Phase 2/3 Completed 596 enrolled Eli Lilly and Company BioMS Technology Corp. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.

Timeline

Start: 2004-12
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dirucotide	Protein / enzyme biologic	500 mg	Intravenous

A Study for Patients With Secondary Progressive Multiple Sclerosis

Summary

Timeline

Drugs

Indications